The clinical significance of low-frequent RAS pathwaymutated alleles and the optimal sensitivity cutoff value in the prediction of response to anti-EGFR therapy in metastatic colorectal cancer (mCRC) patients remains controversial. We aimed to evaluate the added value of genotyping an extended RAS panel using a robust nanofluidic digital PCR (dPCR) approach. A panel of 34 hotspots, including RAS (KRAS and NRAS exons 2/3/4) and BRAF (V600E), was analyzed in tumor FFPE samples from 102 mCRC patients treated with anti-EGFR therapy. dPCR was compared with conventional quantitative PCR (qPCR). Response rates, progression-free survival (PFS), and overall survival (OS) were correlated to the mutational status and the mutated allele fraction. Tumor response evaluations were not available in 9 patients and were excluded for response rate analysis. Twenty-two percent of patients were positive for one mutation with qPCR (mutated alleles ranged from 2.1% to 66.6%). Analysis by dPCR increased the number of positive patients to 47%. Mutated alleles for patients only detected by dPCR ranged from 0.04% to 10.8%. An inverse correlation between the fraction of mutated alleles and radiologic response was observed. ROC analysis showed that a fraction of 1% or higher of any mutated alleles offered the best predictive value for all combinations of RAS and BRAF analysis. In addition, this threshold also optimized prediction both PFS and OS. We conclude that mutation testing using an extended gene panel, including RAS and BRAF with a threshold of 1% improved prediction of response to anti-EGFR therapy.
Introduction
Cetuximab and panitumumab are monoclonal antibodies that inhibit the activation of the EGFR pathway (namely the RAS-RAF-MAPK and PI3K-PTEN-AKT) and concomitant detection of mutations in downstream effectors, mainly KRAS (exon 2), improves the selection of candidate metastatic colorectal cancer (mCRC) patients that benefit from anti-EGRF therapy (1, 2). However, recent studies have demonstrated that other RAS mutations (exons 3 and 4 of KRAS and exons 2,3 and 4 of NRAS) are predictive of resistance to anti-EGFR drugs (3, 4) . These findings led most of the regulatory agencies and the major clinical guidelines to restrict the use of cetuximab and panitumumab to patients with wild-type RAS (including KRAS exons 2/3/4 and NRAS exons 2/3/4) tumors. Unfortunately, not all wild-type RAS patients respond to anti-EGFR therapy and optimization of the predictive model is still needed.
Other downstream mutations in the pathway may confer resistance to anti-EGFR treatments similar to RAS mutations (5) (6) (7) (8) . Some authors and guidelines recommend avoiding anti-EGFR therapies in BRAF V600E-positive patients, although clinical evidence for definitive statements are insufficient (9) (10) (11) .
No clearly standardized procedures for KRAS/NRAS mutational testing have been proposed and established (12, 13) and an increasing number of techniques have been developed with different levels of sensitivity and specificity (12, (14) (15) (16) (17) (18) (19) (20) (21) . Several highly sensitive techniques are currently being evaluated. Among them, digital PCR (dPCR) is an increasingly applied technique that offers a number of advantages for both detecting and quantifying nucleic acids (22, 23) .
However, the clinical significance of low fraction of RASmutated alleles detected with highly sensitive techniques in relation to the effectiveness of anti-EGFR therapy in mCRC remains unclear and needs to be established. Recently, LaurentPuig and colleagues (24) has evaluated the role of minor mutated KRAS sub-clones in patients with mCRC treated with anti-EGFR drugs using picoliter multiplex droplet dPCR. A threshold of 1% of KRAS exon 2-mutated clones was determined as optimal to distinguish responder from nonresponder populations.
The aim of our study was to evaluate whether the extended RAS pathway genotyping using a highly sensitive nanofluidic dPCR improves the prediction of response to anti-EGFR therapy in mCRC patients.
Materials and Methods

Patients and samples
We retrospectively analyzed 102 patients with histologically confirmed mCRC. Formalin-fixed paraffin-embedded (FFPE) primary tumors were obtained from surgical resections (partial or complete colectomy) carried out between 1997 and 2011 at the University Hospital of Bellvitge, University Hospital del Mar and Vall d'Hebron University Hospital. Main clinicopathologic characteristics of the patients are described in Table 1 . Pathologic diagnosis was verified on the basis of hematoxylin and eosin (H&E)-stained sections and carcinomas were classified according to UICC TNM classification system. Before DNA extraction, stained slides were reviewed by a pathologist to estimate overall neoplastic cell content. Among the tumor samples, 88% had a tumor cell content of 50% or more, and the remaining contained between 10% and 45% of tumor cells. All patients were treated with cetuximab or panitumumab as per label indication. Accordingly, primary tumors from 64 patients were tested for KRAS exon 2 mutations by the therascreen KRAS PCR Kit (Qiagen) and for 38 patients anti-EGFR therapy was given before label required KRAS exon 2 negative results. The majority of patients received cetuximab and irinotecan after irinotecan-based chemotherapy failure (87 out of 102 patients) as referred in Table 1 . We considered patients with chemorefractory disease after fluoropyrimidine, oxaliplatin, and irinotecan failure in the metastatic setting. We also considered patients treated with oxaliplatin in an adjuvant setting who have progressed during or within 6 months of treatment completion and received an irinotecan-based regimen in first line. Tumor response was extracted from medical records evaluated by attending physician, according to RECIST criteria. Patients with stable disease (SD) or disease progression (PD) were defined as nonresponders (25) . Independent ethics committees at each participating center reviewed and approved the protocol and the study was carried out according to the principles of the Declaration of Helsinki. Committees allowed a waiver in individual patient consent for retrospective biomedical research studies, which included the permission to use patients' samples without informed consent in case of death.
DNA extraction and primary PCR reactions
DNA from FFPE tissues was extracted using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. DNA quality and concentration were measured with a NanoDrop 1000 spectrophotometer (Thermo Scientific).
We used a two-step PCR to increase yield. In the first PCR, nine amplicons (4 for KRAS, 4 for NRAS and 1 for BRAF, Supplementary Table S1 ) were amplified for each sample. Fifty ng of DNA was used to amplify using external primers for 14 cycles of 30 seconds at 95 C, 30 seconds at the corresponding annealing temperature (Supplementary Table S1 ), and 30 seconds at 72 C, including a final extension step in a Mastercycler proS (Eppendorf). Amplified DNA was used as a template for a nested PCR (both nanofluidic dPCR and conventional qPCR). The specific point mutations analyzed are specified in Supplementary Table S2 .
Mutations in KRAS (exons 2/3/4), NRAS (exons 2/3/4), and BRAF (V600E) were detected by conventional qPCR (sensitivity of about 1%-10%) and by nanofluidic dPCR (sensitivity of about 0.05%-0.1%) of genomic DNA as previously described (23) .
Briefly, nanofluidic dPCR was performed using the Digital Array (Fluidigm Europe B.V., Amsterdam, the Netherlands), an array that partitions a sample premixed with PCR reagents into 770 individual PCR reactions allowing for absolute quantification of target sequences. External primers to complementary probe regions and TaqMan MGB probes (Applied Biosystems, Life Technologies corp., Spain) to screen a panel of 34 hotspots. For each allele to test, one probe targets the wild-type variant (tagged with VIC fluorophore) and a second one targets to mutated variant (tagged with FAM fluorophore). Six mL reaction mixes containing 3 mL of master mix, 0.6 mL of the 20Â GE Sample Loading Reagent, 0.3 mL of DNA-free water, 0.3 mL of 20x genespecific assays (TaqMan probes specific for mutated and wild-type sequence), and 1.8 mL of amplified DNA sample were prepared. Five mL of the reaction mixture was loaded onto a digital array. The digital array was thermocycled on the BioMark Real-Time PCR System (Fluidigm Europe B.V.). The BioMark Digital PCR Analysis Software was used to process the data, mutated allele frequencies for a given case were calculated using the formula: Number of mutated alleles detected by a given probe/total number of alleles analyzed per genomic position. The real-time conventional assay (qPCR) was performed using the same set of primers and probes using the real-time PCR machine Light Cycler 480 (Roche Life Science). One mL of amplified genomic DNA was added in 2.5 mL TaqMan universal PCR Master Mix, 0.125 mL of 40X probes mix and 1.375 mL of H 2 0. The thermal cycling parameters are the same for all alleles tested: 95 C for 10 minutes, 40 cycles at 92 C for 15 seconds and annealing temperature at 60 C for 1 minute. A final step of allelic discrimination is necessary to differentiate between VIC and FAM signals. The Light Cycler 480 Software v1.5 determines the genotype of the sample by measuring the intensity distribution of used dyes after PCR.
Statistical analysis
For survival analyses, we used the Cox proportional regression model adjusting for age, gender, and number of chemotherapy treatment lines before the anti-EGFR treatment. HRs and 95% confident intervals (CI) were calculated. We estimated survival curves using the Kaplan-Meier method. We analyzed progressionfree survival (PFS) and overall survival (OS) after anti-EGFR treatment according to the mutational status and the mutated allele fraction. PFS was defined as the time from anti-EGFR treatment start to disease progression or death. OS after anti-EGFR treatment was defined as the time from anti-EGFR therapy start to patient death from any cause or the last follow up visit. Patients for which the radiologic data were not available were censured at the last follow-up.
Independently from the survival analysis, to evaluate the best sensitivity threshold for mutations to predict treatment response, we calculated ROC curves, comparing them by bootstrap using the R library pROC. In this analysis, only patients with an evaluable radiologic response were considered (N ¼ 93).
In addition, to compare the predictive value of different mutational profiles we defined three different scenarios of analysis: (i) KRAS (exon 2); (ii) RAS (KRAS exons 2/3/4 and NRAS exons 2/3/4); (iii) RAS and BRAF.
Data were analyzed with statistical software R version 3.1.2.
Results
Mutational profiling detected by conventional qPCR and highly sensitivity dPCR Twenty-two of 102 (22%) tumors harbored one mutation detected by qPCR with no cases of multiple mutations detected. None of these mutations were observed in the 64 patients with wild-type KRAS exon 2 tumors, analyzed routinely by the therascreen KRAS PCR Kit. All these tumors were also scored as positive with dPCR and the percentage of mutated alleles ranged from 2.1% to 66.6% (median: 35.84%). Analysis by dPCR increased the number of patients bearing mutations up to 48 (47%) and identified multiple additional low-frequency mutated alleles in 12 cases (Supplementary Table S3 ). The percentage of mutated alleles in this set of 26 patients detected only by dPCR ranged from 0.04% to 10.8% (median: 1.26%). The most frequently detected mutations by qPCR were KRAS (11/102; 11%) followed by NRAS (6/102; 6%) and BRAF (5/102; 5%). Sixtythree mutations were identified by means of dPCR. In this setting, KRAS mutations were further overrepresented (40/102; 39%) followed by NRAS (12/102; 12%) and BRAF (5/102; 5%). The frequencies of mutation of individual exons in the populations of patients with mutations are shown in Table 2 .
Response to anti-EGFR therapies
Radiologic tumor response was evaluable in 93 of the 102 patients (in 9 patients was non-evaluable and these patients were omitted from the analysis). The overall response rate (ORR) was 32.3%, including 1 complete response and 29 partial responses. Analysis of KRAS exon 2 by conventional qPCR (Fig. 1A) identified 7 mutated cases, all of them nonresponders. This reclassification translated into a higher ORR (34.9%) in the KRAS exon 2 wild-type subgroup. Extended RAS identified 8 additional mutated cases modestly increasing ORR to 37.2% in the RAS wild-type population, albeit one partial response was evidenced in a mutated case (ORR of reclassified mutated patients was 6.7%). BRAF genotyping identified 5 additional mutated cases, all of them nonresponders, increasing ORR up to 39.7% in the RASþBRAF wild-type population. The ORR of reclassified RASþBRAF-mutated patients with qPCR was 5% (1/20). No statistically significant differences in ORR between sensitive and chemorefractory population were observed (Supplementary Table S4) .
Compared with conventional qPCR, qualitative dPCR genotyping (limit of detection of the technique, 0.05%-0.1% of mutated alleles) of KRAS exon 2 identified 16 additional mutated cases (Fig. 1C) . ORR in the selected wild-type population was 37.1% whereas ORR in patients with reclassified as KRAS exon 2-mutated tumors was 17.4% (4 responders out of 23 patients). The extended RAS genotyping reclassified 16 additional mutated cases (3 of them responders) which translate into a higher ORR (42.6%) in the RAS wild-type cases. The ORR among the RAS extended mutated reclassified group was 17.9% (7/39). Finally, the BRAF analysis did not add any additional mutation to the qPCR analysis. ORR in this RASþBRAF wild-type subset was 46.9% whereas ORR in patients reclassified as RASþBRAF mutated by qualitative dPCR was 15.2% (7/46). We then assessed the correlation of the relative abundance of the mutated allele as assessed by dPCR and response rate. As expected, an inverse correlation between the proportion of mutated allele and the anti-EGFR response was evident. The mean percentage of mutated DNA was 0.5% for responders (range, 0.1%-8.1%) and 11.7% for nonresponders (range, 0.05%-66.6%; P < 0.005; Fig. 2 ). Considering the entire the mutated cases detected by qualitative dPCR genotyping, 7 responders would have been scored as positive. Of note, the relative abundance of the major mutated allele ranged between 1% and 10% in three of them, whereas in the remaining 4 patients the major mutated allele frequency was below 1%.
The ROC curve bootstrap analysis was performed to estimate the optimal clinically relevant threshold cutoff value of mutated alleles in the prediction of response. For dPCR the categorization of a fraction of 1% or higher for any mutated allele offered the best area under the curve (AUC) value for all combinations of RAS and BRAF analysis (Supplementary Table S5 ) delivering the best balance between sensitivity and specificity. A fraction lower than 1% for any mutated allele does not change significantly the AUC estimation. When compared with qPCR the use of dPCR using the 1% cutoff value (Fig. 1B ) reclassified 9 cases into mutated for KRAS exon 2, 13 when we extend to all RAS cases and additional 5 cases for RASþBRAF. This reclassification improved anti-EGFR response rate in KRAS exon 2, in the RAS and in the RAS þ BRAF wild-type subgroups with an increase in the ORR up to 37.6%, 42.2%, and 45.8%, respectively. In this setting, only 3 responding patients were classified as mutated. The ORR of patients reclassified as mutated for KRAS exon 2, RAS extended and RASþBRAF was 6.2%, 10.3%, and 8.8%, respectively. When compared with qualitative detection of dPCR (without cutoff value, only the limit of detection of the technique 0.05%-1%) the use of the 1% cutoff value (Fig. 1B and C) reclassified as wild-type 10 patients: 4 responders and 6 nonresponders. Of the 6 nonresponder cases now reclassified as wild-type, 3 had SD while in the remaining 3 disease progressed.
Progression-free survival and overall survival
A clear and significant benefit to anti-EGFR treatment in terms of PFS and OS was apparent in patients with wild-type tumors (Table 3) . Patients with KRAS exon 2-mutated tumors assessed by qPCR had a modestly increased risk of disease progression (HR, 2.83; 95% CI, 1.05-7.62; P ¼ 0.064) with an impact on OS (HR, 2.70; 95% CI, 1.13-6.46; P ¼ 0.047). The relative risk was higher when any mutation was considered (HR, 5.36; 95% CI, 2.57-11.18). Similar results were observed when we analyzed the mutational status by dPCR. Survival analyses taking into account only KRAS exon 2 hotspots showed that patients with more than 1% of mutated allele fraction presented a HR of 3.43 (95% CI, 1.67-7.02) and 2.72 (95% CI, 1.52-4.88) for PFS and OS, respectively, compared with wild-type patients or with less than 1% of mutated allele fraction. When we extended the analysis to RAS and BRAF and a threshold of 1%, the 37 mutated cases presented a HR of 4.52 (95% CI, 2.25-9.07) and 2.5 (95% CI, 1.57-4.02) for PFS and OS, respectively. We obtained similar results when dPCR results were categorized as positive or negative irrespective of the relative abundance of the mutated allele (qualitative detection limited by the sensitivity of the technique). In concordance with AUC depicting 1% as the best cut-off value, a 2% cutoff value resulted in a poorer discrimination of PFS and OS (Supplementary Table S6 ).
Discussion
In this study, we have shown that the use of an extended gene panel testing RAS and BRAF hotspot mutation with the highly sensitive nanofluidic dPCR improved the prediction of response to anti-EGFR therapy when a threshold of 1% is used. Our data are consistent with other studies reported recently (3, 24) . LaurentPuig and colleagues suggested that patients with mCRC with KRAS exon2-mutated subclones (lower or equal to 1%) had a benefit from anti-EGFR therapy (24) . Similarly, data reported on RAS extension mutations analyzed by BEAMing in the KRAS exon 2 wild-type cohort of patients enrolled in the CRYSTAL trial showed different outcomes depending on the cutoff value of mutated/wild-type. Using a 5% cutoff value of RAS mutations was scored in 14.7% of patients whereas using a cutoff value of 0.1% RAS mutations was scored in 20% of patients. They concluded that mCRC patients with tumors bearing mutations between 0.1% and <5% may have benefited from the addition of cetuximab to chemotherapy in the first-line setting (3).
Highly sensitive dPCR used qualitatively (sensitivity 0.05%-0.1%) more than doubled the number of patients scored as positive compared with qPCR. Moreover, an inverse correlation between the relative abundance of mutated alleles and anti-EGFR response was observed (P < 0.005). A fraction of 1% or higher for any mutated allele offered the best predictive value for all combinations of RAS and BRAF mutation analysis. When compared with qPCR the use of dPCR using 1% cutoff value reclassified 9 more patients mutated for KRAS exon 2 and 14 more patients when all RAS mutations were analyzed. This reclassification impacts in treatment response and survival compared with qualitative dPCR analysis. However, these results must be assessed with caution because still 3 of 29 RAS-mutated patients achieved a response and the ORR of these reclassified RAS mutated is 10% (3 responders in 29 total mutated). When BRAF was added to the analysis, 5 patients were reclassified as mutated (by qPCR and dPCR) and all 5 progressed. The ORR of reclassified mutated patients, including RASþBRAF decreased to 8.8% (3 responders in 34 total mutated). These figures are close to the ORR of mutated RAS extended analysis with conventional qPCR (1/15; 6.7%) in this series and to others in the literature (8) .
As expected, the presence of mutations in KRAS exon 2, RAS extended or RASþBRAF was associated with significant worse PFS and OS, either by qPCR or dPCR. Interestingly, median PFS and OS were better in the group of patients with mutations in the tumor detected by dPCR than those with mutations detected by qPCR, suggesting that a minimum of mutated alleles are required to confer complete resistance to anti-EGFR therapies. The 1% cutoff value allowed us to define a more accurate group of patient candidates to anti-EGFR treatment. When a cutoff value of 2% was applied, differences between wild-type and mutated tumors, in terms of PFS and OS, were lower (Supplementary Table S6 ).
Except for extended RAS mutations (4), none of the other candidate genes BRAF or PIK3CA have been completely validated in large clinical trials yet (8, (26) (27) (28) . Nevertheless, the low frequency of such mutations makes difficult to define the negative predictive value they harbor.
BRAF V600E mutations have been reported in 5% to 15% in clinical trial series. The percentage of mutation in a Nordic nonclinical trial population was 21% (29) . This variability in the series can be partly explained by the fact that BRAF mutations are associated with poor clinical features and worse OS in mCRC patients (30, 31) , limiting the inclusion of BRAF-mutated tumors in series of chemorefractory advanced patients treated beyond the first line setting. As a negative prognostic marker, BRAF mutations can act as a confounding variable when assessing their predictive value in the first line setting of advanced disease (32) (33) (34) . In our series, we detected a BRAF mutation in five patients by both techniques (5%). Efficacy outcomes were consistent with data reported previously and BRAF-mutated patients had worse survival and response rate.
The potential negative predictive value of PIK3CA mutations to anti-EGFR is still controversial. Mutations in PIK3CA exon 9 frequently coexist with KRAS mutations, but only exon 20 mutations were associated with resistance to treatment (8) . We also analyzed mutations in hotspots of exon 20 of PIK3CA (data not shown) that were detected at very low-frequency not adding relevant information for the clinician in the decision-making process. For the sake of clarity, this information has not been included in the present article.
The methodology used in this study provides with a robust approach to the analysis of suboptimal samples. Initially, we were not able to obtain consistent results without preamplification likely due to the degradation of DNA extracted from FFPE samples. Subsequently, we established that 14 were the optimal number of pre-amplification cycles needed to obtain robust results maintaining its quantitative power when using dPCR. It is noteworthy that with the modified approach we have validated the 1% threshold value that was initially reported with no preamplification step (24) .
In summary, our study supports the use of anti-EGFR therapy in patients with RAS and BRAF wild-type tumors, which allow us to define a more accurate group of patients more likely to benefit from cetuximab-and panitumumab-based therapy. In addition, despite several commercial kits are being used in daily clinical practice for mutational testing, the screening of mutations by means of highly sensitive techniques such as dPCR should lead to a higher detection of mutations in colorectal cancer samples. Moreover, the 1% cutoff value seems to be the more appropriate value for determining the eligibility for anti-EGFR drugs in the chemorefractory setting. The additional value of our study is the confirmation of this 1% cutoff value not only for KRAS exon 2 mutations but also for an extended hotspot panel of genes in the RAS pathway (KRAS, NRAS, and BRAF). Nevertheless, a proportion of patients reclassified as mutated in our study (10%) achieved tumor response, effect that may be driven by chemotherapy only. It is necessary to perform prospective and larger studies to establish a mutation detection threshold that is clinically relevant to select patients for anti-EGFR therapy.
Conclusions
The addition of simultaneous detection and quantification of extended KRAS (exons 3/4), NRAS and BRAF mutations to the conventional standard KRAS (exon 2) mutational analysis with highly sensitive nanofluidic dPCR array platform improved the prediction of response to anti-EGFR therapy in mCRC patients adequately classifying a significant proportion of cases. The quantification and detection of major allele frequency and low-frequency mutated alleles may provide new insights into the role of genes involved in the EGFR-dependent signaling pathways.
